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Abstract 
Measures of health-related quality of life (HRQL) and other patient-reported outcomes (PRO) 
generate important data in cancer randomized controlled trials (RCTs) to assist in evaluating 
the risks and benefits of cancer therapies, and fostering patient-centered cancer care.  
However, the various ways these measures are analyzed and interpreted make it difficult to 
compare results across trials, and hinders the application of research findings to inform 
publications, product labelling, clinical guidelines and health policy. To address these 
problems, the Setting International Standards in Analyzing Patient-Reported Outcomes and 
Quality of Life Endpoints Data (SISAQOL) initiative has been established. This international 
multidisciplinary consortium, directed by the European Organization for Research and 
Treatment of Cancer (EORTC), was convened to provide recommendations to standardize 
the analysis of HRQL and other PRO data in cancer RCTs. This article discusses the 
reasons why this project was initiated, the rationale for the planned work, and the expected 
benefits to cancer research, patient/provider decision-making, care delivery, and 
policymaking.  
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Introduction 
Patient-centeredness is increasingly identified as a critical component of quality health care.1 
With an enhanced emphasis on patient-centered care, health-related quality of life (HRQL), 
and other patient-reported outcomes (PRO) that quantify how a patient feels and/or 
functions, are assuming a more prominent role as important endpoints in cancer clinical 
trials.2,3  
7KHWHUPV³PRO´ and ³+54/´ have at times been used interchangeably, leading to 
confusion in terminology.4 However, PRO and HRQL are two distinct terms that complement 
each other.  Patient-reported outcome is defined as any clinical outcome that is reported 
directly by  the patient;  PRO can be captured either through self-report or interview, as long 
as the interviewer directly UHFRUGVWKHSDWLHQW¶VUHVSRQVHs.5,6  Health-related quality of life, 
which is often assessed as a PRO, is a multidimensional concept that refers to the SDWLHQW¶V
subjective perception of the impact of his/her disease and treatment(s) on physical, 
psychological, and social aspects of daily life.6,7 Many HRQL questionnaires also cover 
symptoms of disease, functional impairments, and adverse effects of treatment. This 
distinction between PRO and HRQL implies that PRO can be used to measure constructs 
other than HRQL (e.g., adherence, experiences of care) on the one hand, and HRQL can be 
measured by means other than PRO (e.g., observer or proxy reports) on the other hand.  
Expanding adoption of PRO measures has revealed important challenges: the diverse ways 
of analyzing and interpreting PRO endpoints make it difficult to compare results across 
various cancer clinical trials. A continuing lack of standardization risks the suboptimal use of 
these findings to inform both policy and treatment decisions, and results in an inefficient use 
of increasingly finite research funding.8  Moreover, improved standardization of endpoint 
definitions, as well as the analysis and presentation of PRO data would strengthen the 
rationale for the use of PRO endpoints and generate rigorous data needed  to power future 
trials that could statistically test important PRO hypotheses, thereby complementing 
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traditional radiologic and survival based endpoints.9 What is promising is the increased 
awareness in the research community that this issue needs to be addressed. Efforts to 
standardize specific aspects of PRO evaluations in cancer clinical trials are underway.  For 
example, recent and ongoing efforts have focused on standardizing the outcomes to be 
measured,10-12  the content that should be included in protocols (Standard Protocol Items: 
Recommendations for Interventional Trials in Patient Reported Outcomes -- SPIRIT-
PRO),13,14 and the reporting of clinical trials findings (ISOQOL reporting standards; 
CONsolidated Standards of Reporting Trials in Patient Reported Outcomes -- CONSORT-
PRO).15,16 While these efforts have emphasized standards for collecting and reporting PRO 
data, guidelines and best practices for the analysis and interpretation of PRO endpoints in 
cancer clinical trials are lacking.  
Main Objective 
SISAQOL is a collaborative initiative assembled by the EORTC to address this gap. This 
international consortium will develop recommendations for standardizing the analysis and 
interpretation of PRO endpoints in randomized cancer clinical trials.  
These recommendations will not be tailored to a specific questionnaire; rather they will be 
broad enough to be applicable across different types of PRO measures (e.g., traditional 
fixed-length questionnaires, as well as more flexible assessment tools such as computer 
adaptive tests). Indeed, although the algorithm to compute the outcome scores from different 
types of measures may differ, the challenges encountered to analyze and interpret these 
scores are similar. 
As an initial goal, SISAQOL will focus on standardizing the analysis of HRQL as measured 
by PRO, with a view towards broadening its scope to include other ways of measuring HRQL 
(e.g., observer or proxy-reports) and other types of PRO (e.g., treatment adherence, 
satisfaction with care).  
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Individuals or parties interested in contributing to this consortium, please visit us at (enter 
website here) for more details. 
What is the problem? 
Imagine that a randomized controlled trial (RCT) was conducted to assess the relative 
efficacy of two cancer treatments (A and B). Patients reported their level of physical 
functioning (measured using a multi-item scale) at baseline and every 6 weeks thereafter 
until disease progression or 
study discontinuation. 
Several analyses could be 
conducted, for example: a) 
time to deterioration of 
patient-reported physical 
functioning compared to 
baseline; b) between-group 
differences in overall means; 
and c) cross sectional 
comparison at a specific 
time point (i.e., end of treatment; hypothetical findings are shown in Figure 1). Results would 
reveal that the time to deterioration analysis favored Treatment B (12 weeks vs 42 weeks), 
overall means would not favor either treatment , and examining differences at end of 
treatment would tend to favor treatment A. What conclusions could then be drawn from this 
trial?  
Although this is a hypothetical example, several examples do exist in the literature where 
different methods of analysis applied within one RCT or variations in applied methods in 
different RCTs in the same patient population produced seemingly contradictory results.17-19 
Such inconsistencies cast doubt on HRQL and other PRO findings in RCT publications, and 
Figure 1. Mean physical functioning scores at every assessment 
point for each treatment group. Results from a) time to 
deterioration analysis are represented with arrows, b) 
comparison of group means across time are represented with 
dashed lines, and c) comparison of group means at a single 
time point are represented by the bold faced values. 
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may impact the overall risk/benefit assessment of drugs and the decisions to register, 
reimburse and/or use these agents in the clinic.  
How did this problem emerge?   
7KHSUREOHPRILQFRQVLVWHQF\LQWKHDQDO\WLFDSSURDFKWR+54/HQGSRLQWVGRHVQRWVWHP
IURPWKHUHOHYDQFHRIWKHGDWDRUWKHTXDOLW\RIWKHLQIRUPDWLRQWKDWFDQEHH[WUDFWHGIURPWKH
GDWD5DWKHUWKHSUREOHPLVWKDWPDQ\GLIIHUHQWUHVHDUFKTXHVWLRQVFDQEHDVNHGDERXW
+54/DQGRWKHU352RXWFRPHV7KHUHIRUHFOHDUDQGZHOO-GHILQHGUHVHDUFKTXHVWLRQVPXVW
EHVHOHFWHGDSULRULDQGPDWFKHGZLWKDSSURSULDWHVWXG\GHVLJQDQGDQDO\VHV)XUWKHUPRUH
ZKLOHJXLGHOLQHVZRXOGVXJJHVWWKDWWKHDQDO\WLFFRQVLGHUDWLRQVIRU+54/DQGRWKHU352
HQGSRLQWVDUHVLPLODUWRWKRVHIRURWKHUWULDOHQGSRLQWVWKHGDWDJHQHUDWHGIURP+54/DQG
RWKHU352PHDVXUHVDUHPRUHFRPSOH[UHTXLULQJUHVHDUFKHUVWRPDNHGLIIHUHQWGHFLVLRQV
IRUHDFKSDUWRIWKHDQDO\VLV6SHFLILFDOO\PDQ\352LQVWUXPHQWVWKDWPHDVXUH+54/DUH
PXOWLGLPHQVLRQDOZLWKVHYHUDOVXEVFDOHVWRFKDUDFWHUL]HWKHLPSDFWRQDVSHFWVRISDWLHQW
IXQFWLRQLQJDQGVRPHWLPHVDQRYHUDOOVFRUHFDQEHGHULYHGIURPWKHVHVXEVFDOHVWR
VXPPDUL]HWKHSDWLHQW¶VVHOI-UHSRUWHGKHDOWK0RUHRYHU+54/LQVWUXPHQWVFRXOGDOVR
LQFOXGHDGGLWLRQDOVXEVFDOHVRUVLQJOHTXHVWLRQVWKDWFDSWXUHSK\VLFDORUPHQWDOV\PSWRPVRI
GLVHDVHDQGRUDGYHUVHHIIHFWVRIWUHDWPHQW7KLVULFKGLVDJJUHJDWHGGDWDPD\QRWEHSDUWRI
WKHRULJLQDOD-SULRULSODQQHG+54/HQGSRLQWDQDO\VLVEXWDUHVWLOOLPSRUWDQWWRUHSRUW
GHVFULSWLYHO\DVWKH\QRWRQO\SURYLGHWKHSDWLHQWSHUVSHFWLYHRQWUHDWPHQWHIIHFWLYHQHVVDQG
WR[LFLW\EXWDOVRJHQHUDWHQHZUHVHDUFKK\SRWKHVHVWKDWFDQEHIXUWKHUWHVWHGLQWKHIXWXUH,W
LVKRZHYHUFUXFLDOWKDWVXFKXQSODQQHGDQDO\VHVLHH[SORUDWRU\DQDO\VHVVKRXOGEH
VWDWHGDVH[SORUDWRU\DQGWKHILQGLQJVVKRXOGEHLQWHUSUHWHGZLWKFDXWLRQ)LQDOO\WKLV
LQIRUPDWLRQFDQDOVRVXSSOHPHQWRWKHUGDWDHJFOLQLFLDQ-UHSRUWHGWR[LFLW\XVLQJ&RPPRQ
7HUPLQRORJ\&ULWHULDIRU$GYHUVH(YHQWV&7&$(DQGLVLPSRUWDQWWRWKHGHOLYHU\RISDWLHQW
FHQWHUHGFDUH 
6HFRQGFRPSOH[LW\LVLQFUHDVHGJLYHQWKHUHSHDWHGPHDVXUHPHQWVUHTXLUHGWRFDSWXUH
FKDQJHVLQ+54/DQGWKHLQWHUDFWLRQEHWZHHQ+54/DQGWKHWUHDWPHQWXQGHUHYDOXDWLRQ
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/DVWO\PLVVLQJ+54/GDWDDUHDQLQKHUHQWSUREOHPDQGFDQEHGHSHQGHQWRQSDWLHQWVWDWXV
HJSDWLHQWVZKRGURSRXWRIWKHVWXG\EHFDXVHWKH\DUHQRWGRLQJZHOOWKXVVWDWLVWLFDO
DQDO\VHVPXVWDFFRXQWIRUGDWDWKDWDUHPLVVLQJQRWDWUDQGRP7KHPXOWL-GLPHQVLRQDO
QDWXUHRI+54/FRPELQHGZLWKUHSHDWHGPHDVXUHPHQWVDQGWKHSUHYDOHQFHRIPLVVLQJ
GDWDLQYLWHVPXOWLSOHVWDWLVWLFDOWHVWVDQGLQIODWHGW\SHHUURU0DQ\RIWKHVHLVVXHVDUHDOVR
UHOHYDQWZKHQPHDVXULQJPRUHSUR[LPDOXQLGLPHQVLRQDO352DQGRU+54/FRQFHSWVVXFK
DVLQGLYLGXDOV\PSWRPVRUSK\VLFDOIXQFWLRQ:HEHOLHYHWKDWDODFNRIFOHDUJXLGDQFHDQGWKH
ODFNRILQWHUQDWLRQDOO\UHFRJQL]HGVWDQGDUGL]HGPHWKRGVWRDQDO\]HDQGUHSRUW+54/DQG
RWKHU352GDWDKDYHFRQWULEXWHGWRDSUREOHPWKDWLVDOUHDG\FRPSOLFDWHG 
8OWLPDWHO\UHVHDUFKHUVSODQWRFRQGXFWWKHPRVWDSSURSULDWHDQDO\VLVRI+54/DQGRWKHU
352PHDVXUHV+RZHYHUWKHODFNRIVSHFLILFUHVHDUFKTXHVWLRQVDQGWKHPDQ\SRVVLEOH
ZD\VWRDQDO\]H+54/DQGRWKHU352GDWDFDQOHDGWRGLIIHUHQWDQDO\WLFGHFLVLRQVDQGLQ
WKHDEVHQFHRIJXLGDQFHWKHUHVHDUFKHULVOHIWWRGHFLGHKRZWKHDQDO\VLVVKRXOGEH
FRQGXFWHG6RPHLQYHVWLJDWRUVIDYRUHDVHRIUHSRUWLQJWRFOLQLFLDQVHJSURGXFHGHVFULSWLYH
VWDWLVWLFVZKHUHDVRWKHUVIDYRUVWDWLVWLFDOFRUUHFWQHVVHJFRPSOH[PRGHOOLQJDSSURDFKHV
WKDWPD\QRWEHDVHDVLO\FRPPXQLFDWHGWRFOLQLFLDQV,GHDOO\WKHPRVWDSSURSULDWHZRXOG
EHDFRPELQDWLRQRIWKHWZRSUH-VSHFLILHGUREXVWVWDWLVWLFDOPRGHOLQJFRPSOHPHQWHGE\
UHSRUWLQJLQFOXGLQJJUDSKLFDOSUHVHQWDWLRQWKDWLVHDVLO\LQWHUSUHWHGE\FOLQLFLDQV,WLV
WKHUHIRUHQRWVXUSULVLQJWKDW+54/DQGRWKHU352ILQGLQJVLQ5&7VVWHPIURPDYDULHW\RI
VWDWLVWLFDODSSURDFKHVOHDGLQJWRUHVXOWVWKDWPD\QRWEHGLUHFWO\FRPSDUDEOH7KLVLVD
FULWLFDOLVVXHWKDWFDQQRWEHLJQRUHGHVSHFLDOO\DVFOLQLFDOUHVHDUFKDQGFDUHPRYHWRZDUGVD
PRUHSDWLHQW-FHQWHUHGDSSURDFKLQZKLFK+54/DQGRWKHU352VSOD\DFHQWUDOUROHLQ
KHDOWKFDUHGHOLYHU\ 
Towards a solution 
A multi-disciplinary expert Consortium (represented by the authors) has been established to 
develop consensus on international standards for the analysis of HRQL and other PRO data 
in cancer clinical trials. In assembling the expert Consortium, it is crucial that key 
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stakeholders are involved so that the insights gathered from this initiative are technically 
correct, comprehensive, and balanced.  Therefore, the group is comprised  of not only 
leading HRQL researchers and statisticians, but also key individuals from various 
international oncologic and medical societies, advisory and regulatory bodies, academic 
societies, pharmaceutical industry, cancer institutes and, crucially patient advocacy 
organizations. It is our hope that with this collaborative work we will be able to set standards 
for the analysis of HRQL and PRO data that will be acceptable to all parties.  
Our first step has been to explore the different perspectives and views of the Consortium 
members. There was a clear consensus that standards and best practices for the analysis of 
HRQL and other PRO data are lacking and that such guidance is urgently needed.  We 
developed an initial work plan, which focuses on appropriate statistical analyses for PRO 
data generated from HRQL instruments in cancer RCTs. We will then expand to other 
clinical trial designs (e.g., non-randomized trials, single arm studies, adaptive design), and 
other types of PRO (e.g., daily diaries). 
To date, the Consortium noted that there is a limited consensus regarding the definitions of 
basic terminology such as compliance rates, baseline, minimally important differences (MID) 
and minimal clinically important differences (MCID), and the population that needs to be 
examined. We intend to identify the critical terms where consensus definitions are  lacking 
and work towards having standardized definitions. Discussion points include, for example, 
(a) having one definition of compliance rate versus having different types of compliance 
rates  (such as number of participants with HRQL at baseline or number assigned to HRQL), 
and (b) the definition of the population data set to be used for analysis  as the intention-to-
treat (ITT) population may not always be appropriate because of the high rates of drop out 
typical of cancer RCTs or the design might not require all randomized patients to be part of 
the HRQL and other PRO assessments. 
11 
 
Next, as mentioned above, a critical issue that surrounds HRQL and other PRO measures in 
RCTs in cancer is missing data. There are many different ways to handle missing data. For 
example, some researchers choose to ignore the missing data, analyzing only available 
data. Others may impute missing data with replacement values such as last value carried 
forward. Yet other approaches use complex statistical models that allow for missing data 
under specific assumptions.26 These different approaches to missing data also influence the 
interpretation of HRQL results.  International guidance and other PRO standards with 
respect to how missing data should be treated would make an important contribution to 
improving the rigor and reproducibility of HRQL findings.  
Moreover, to address the issues around the multiple ways of analyzing and reporting HRQL 
and other PRO measurement results, we plan to conduct a critical review of the literature to 
identify the common statistical analyses used in cancer RCTs and to examine the possibility 
of matching statistical methods to appropriate research questions.  
Finally, for each recommended statistical method, best practices need to be developed to 
ensure a uniform and correct implementation across different statistical assumptions of the 
underlying data. For instance, in what circumstances should models or effect estimates be 
adjusted for baseline measures? What are the considerations for inclusion of other patient-
specific covariates in the analysis? Are sensitivity analyses needed, for example, in relation 
to patterns of missing data, and if so, what types of sensitivity analyses should be 
conducted? Decisions on these more specific options should not be neglected. Even if a 
statistical methodology is broadly agreed upon for a specific research question, a lack of 
consistency in the details of implementing the method can have an important impact on the 
findings. As we move forward, it is crucial that we build on past knowledge and that we 
consider recommendations proposed by the different regulatory bodies (e.g., U.S. Food and 
Drug Administration and European Medicines Agency) and academic societies (e.g., 
International Society for Quality of Life Research, International Society for 
Pharmacoeconomics and Outcomes Research). We will systematically identify relevant 
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guidance, review their recommended methods and determine how the guidance can be 
incorporated into the SISAQOL initiative.  
In developing international consensus on rigorous and reproducible approaches to the 
analysis and interpretation of HRQL data in cancer clinical trials, we will also emphasize a 
pragmatic approach, thereby ensuring that our recommendations are interpretable and 
informative for researchers, clinicians, patients and regulators/policymakers.  The 
overarching goal of this initiative is to support the design, interpretation and reporting of 
HRQL and other PRO endpoints in cancer clinical trials, thereby allowing for new insights 
into the patient experience of treatment effects, and providing reliable and valid information 
for stakeholder decision-making.  
Future steps 
The objective of the SISAQOL initiative is to produce a suite of tools, guidance and 
international consensus standards for the analysis of HRQL and other PRO data from 
clinical trials. We also aim to provide template macros to be used in a number of 
commonplace missing data settings and illustrative macros to address these requirements. 
We expect that having freely available guidelines and tools to facilitate their implementation 
will result in more reliable and faster dissemination of findings that stem from higher quality 
use of statistical methods and improved interpretability due to greater familiarity with 
standardized reporting.  
We are aware that standardizing statistical analyses for HRQL and other PRO data in cancer 
clinical trials is an ambitious goal. However, the need for such standards has become 
prominent given the expanding interest in HRQL and other PRO endpoints. Trials cost 
substantial time, money and effort. Moreover, study participants, in the interest of improving 
their situations and helping others, voluntarily give up their time to complete measures for 
these trials. Therefore, the data we gather from these trials must be exploited to the full, with 
statistical analyses conducted in the most rigorous and standardized fashion, and with 
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results that clearly highlight clinical benefits (not just statistical significance).9 HRQL and 
other PRO findings also have a large potential impact on treatment benefit evaluations; and 
as resources to cover costs of cancer care become scarcer and treatment costs increase, it 
is imperative that these findings are based on valid and reliable statistical methods. For 
these reasons, choosing methods that reflect the best possible available evidence and the 
expertise of a diverse group of stakeholders is crucial.  Members of the SISAQOL initiative 
have a shared interest in addressing this gap by working together to articulate a set of 
standards, best practices, and tools for the analysis and interpretation of HRQL and other 
PRO endpoints in cancer clinical trials. 
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